疫苗接种对慢性阻塞性肺疾病患者急性加重预防研究进展
Research Progress on the Prevention of Acute Exacerbation of Chronic Obstructive Pulmonary Disease by Vaccination
DOI: 10.12677/acm.2024.1451711, PDF,    科研立项经费支持
作者: 李玉烛, 田应选*：西安医学院研究生院，陕西 西安；陕西省人民医院老年病院老年呼吸科，陕西 西安；张 恒：陕西省人民医院老年病院老年呼吸科，陕西 西安
关键词: 慢性阻塞性肺疾病；急性加重；疫苗接种；预防；健康管理；Chronic Obstructive Pulmonary Disease； Acute Exacerbation； Vaccination； Prevention； Health Management
摘要: 疫苗接种是慢性阻塞性肺疾病(COPD)患者重要健康管理措施。研究表明，COPD患者接种流感疫苗、肺炎疫苗具有良好的安全性，能产生较好免疫应答，可以预防和降低COPD急性加重的风险；改善患者临床症状，具备良好的成本效益比。在近年新冠病毒感染流行期的背景下，接种流感疫苗、肺炎疫苗、新型冠状病毒疫苗是一个普遍和持续的现象，这些自然疫源和免疫因素对COPD患者是否可以起到保护作用，产生明确的临床影响是值得思考和探索的问题。本文拟对相关研究数据中针对各类疫苗接种对COPD患者急性加重的影响效果进行综述，为加强COPD患者防治、健康教育及疾病管理提供策略和借鉴。
Abstract: Vaccination is a critical health management measure for patients with chronic obstructive pulmonary disease (COPD). The research indicates that the influenza and pneumococcal vaccines have an excellent safety profile, produce a robust immune response, prevent and decrease the risk of acute COPD exacerbation, and enhance patients’ clinical symptoms. Furthermore, these vaccines have a favorable cost-benefit ratio. During the recent years’ COVID-19 pandemic, vaccination against influenza, pneumonia, and SARS-COV-2 has become a routine measure. The potential protective effects of these natural sources of epidemiology and immunization factors in COPD patients and their clinical impact warrant investigation and consideration. This review intends to review the effects of various vaccines on acute exacerbations of COPD patients in relevant research data, so as to provide strategies and references for enhancing the treatment of COPD patients, health education, and disease management.
文章引用：李玉烛, 张恒, 田应选. 疫苗接种对慢性阻塞性肺疾病患者急性加重预防研究进展[J]. 临床医学进展, 2024, 14(5): 2495-2503. https://doi.org/10.12677/acm.2024.1451711

参考文献

[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版) [J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205. [Google Scholar] [CrossRef] [PubMed]
[2] Wang, C., Xu, J., Yang, L., et al. (2018) Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in China (The China Pulmonary Health [CPH] Study): A National Cross-Sectional Study. The Lancet, 391, 1706-1717. [Google Scholar] [CrossRef] 
[3] Halpin, D.M.G., Celli, B.R., Criner, G.J., et al. (2019) The GOLD Summit on Chronic Obstructive Pulmonary Disease in Low-and Middle-Income Countries. The International Journal of Tuberculosis and Lung Disease, 23, 1131-1141. [Google Scholar] [CrossRef] [PubMed]
[4] Zhou, M., Wang, H., Zeng, X., et al. (2019) Mortality, Morbidity, and Risk Factors in China and Its Provinces, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet Journal, 394, 1145-1158. [Google Scholar] [CrossRef] 
[5] 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版) [J]. 国际呼吸杂志, 2017, 37(14): 1041-1057. [Google Scholar] [CrossRef] 
[6] Decramer, M., Janssens, W. and Miravitlles, M. (2012) Chronic Obstructive Pulmonary Disease. The Lancet Journal, 379, 1341-1351. [Google Scholar] [CrossRef] 
[7] Halpin, D.M.G., Criner, G.J., Papi, A., et al. (2021) Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 203, 24-36. [Google Scholar] [CrossRef] 
[8] Leung, J.M., Niikura, M., Yang, C.W.T., et al. (2020) COVID-19 and COPD. European Respiratory, 56, Article ID: 2002108. [Google Scholar] [CrossRef] [PubMed]
[9] 国家免疫规划技术工作组流感疫苗工作组. 中国流感疫苗预防接种技术指南(2022-2023) [J]. 中华预防医学杂志, 2022, 56(10): 4-34. [Google Scholar] [CrossRef] [PubMed]
[10] Berry, B.B., Ehlert, D.A., Battiola, R.J., et al. (2001) Influenza Vaccination Is Safe and Immunogenic When Administered to Hospitalized Patients. Vaccine, 19, 3493-3498. [Google Scholar] [CrossRef] 
[11] 温莹, 何柳, 翟屹, 等. 流行性感冒病毒裂解疫苗和23价肺炎球菌多糖疫苗改善老年人慢性阻塞性肺疾病的社区干预试验[J]. 中华流行病学杂志, 2018, 39(6): 792-798. [Google Scholar] [CrossRef] [PubMed]
[12] Li, Y., Zhang, P., An, Z., et al. (2022) Effectiveness of Influenza and Pneumococcal Vaccines on Chronic Obstructive Pulmonary Disease Exacerbations. Respirology, 27, 844-853. [Google Scholar] [CrossRef] [PubMed]
[13] Huang, C.L., Nguyen, P.A., Kuo, P., Lian, et al. (2013) Influenza Vaccination and Reduction in Risk of Ischemic Heart Disease among Chronic Obstructive Pulmonary Elderly. Computer Methods and Programs in Biomedicine, 111, 507-511. [Google Scholar] [CrossRef] [PubMed]
[14] 许敏锐, 强德仁, 潘英姿, 等. 慢性病患者接种流感疫苗的效果与效益评价[J]. 公共卫生与预防医学, 2020, 31(5): 21-24. [Google Scholar] [CrossRef] 
[15] 中华预防医学会, 中华预防医学会疫苗与免疫分会. 肺炎球菌性疾病免疫预防专家共识(2020版) [J]. 中华流行病学杂志, 2020, 41(12): 1945-1979. [Google Scholar] [CrossRef] [PubMed]
[16] Kobayashi, M. (2022) Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. Morbidity and Mortality Weekly Report, 71, 109-117. [Google Scholar] [CrossRef] [PubMed]
[17] Ohshima, N., Nagai, H., Matsui, H., et al. (2014) Sustained Functional Serotype-Specific Antibody after Primary and Secondary Vaccinations with a Pneumococcal Polysaccharide Vaccine in Elderly Patients with Chronic Lung Disease. Vaccine, 32, 1181-1186. [Google Scholar] [CrossRef] [PubMed]
[18] 荣恒漠, 杨炯. 肺炎疫苗应用于支气管扩张症及慢性阻塞性肺疾病患者的效果[J]. 武汉大学学报(医学版), 2017, 38(1): 90-95. [Google Scholar] [CrossRef] 
[19] Walters, J.A., Tang, J.N.Q., Poole, P., et al. (2017) Pneumococcal Vaccines for Preventing Pneumonia in Chronic Obstructive Pulmonary Disease. Cochrane Database of Systematic Reviews, 1, CD001390. [Google Scholar] [CrossRef] 
[20] 周志强, 曲建卫, 咸本松, 等. 慢性阻塞性肺疾病患者接种肺炎球菌疫苗疗效的Meta分析[J]. 中华全科医学, 2018, 16(9): 1562-1565, 1574. [Google Scholar] [CrossRef] 
[21] Ignatova, G.L., Avdeev, S.N. and Antonov, V.N. (2021) Comparative Effectiveness of Pneumococcal Vaccination with PPV23 and PCV13 in COPD Patients over a 5-Year Follow-Up Cohort Study. Scientific Reports, 11, Article No. 15948. [Google Scholar] [CrossRef] [PubMed]
[22] 邱英鹏, 赵琨, 李雪, 等. 中国农村老年慢性阻塞性肺病患者接种23价肺炎多糖疫苗的卫生经济学评价[J]. 中华预防医学杂志, 2016, 50(12): 1074-1078. [Google Scholar] [CrossRef] [PubMed]
[23] WHO (2023) WHO Coronavirus (COVID-19) Dashboard.
https://covid19.who.int
[24] 中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版) [J]. 中华临床感染病杂志, 2023, 16(1): 1-9. [Google Scholar] [CrossRef] 
[25] Li, C., Bi, H., Fu, Z., et al. (2022) Retrospective Study of the Immunogenicity and Safety of the CoronaVac SARS-CoV-2 Vaccine in People with Underlying Medical Conditions. Communications Medicine, 2, Article No. 151. [Google Scholar] [CrossRef] [PubMed]
[26] Harboe, Z.B., Hamm, S.R., Pérez-Alós, L., et al. (2022) Antibody Responses and Risk Factors Associated with Impaired Immunological Outcomes Following Two Doses of BNT162b2 COVID-19 Vaccination in Patients with Chronic Pulmonary Diseases. BMJ Open Respiratory Research, 9, e001268. [Google Scholar] [CrossRef] [PubMed]
[27] Zhu, H.H., Sun, G.Q., Wu, J.Y., et al. (2023) Antibody Responses to an Inactivated SARS-CoV-2 Vaccine in Individuals Aged from 50 to 102 Years. Frontiers in Immunology, 14, Article 1212988. [Google Scholar] [CrossRef] [PubMed]
[28] Naaber, P., Tserel, L., Kangro, K., et al. (2021) Dynamics of Antibody Response to BNT162b2 Vaccine after Six Months: A Longitudinal Prospective Study. The Lancet Regional Health—Europe, 10, Article ID: 100208. [Google Scholar] [CrossRef] [PubMed]
[29] Chaiwong, W., Takheaw, N., Laopajon, W., et al. (2022) Neutralizing Antibody and T-Cell Responses against SARS-CoV-2 Wild-Type and Variants of Concern in Chronic Obstructive Pulmonary Disease Subjects after ChAdOx-1/ChAdOx-1 Homologous Vaccination: A Preliminary Study. Vaccines, 10, Article 2176. [Google Scholar] [CrossRef] [PubMed]
[30] Mallah, N., Pardo-Seco, J., López-Pérez, L.R., et al. (2022) Effectiveness of COVID-19 Vaccine Booster in the General Population and in Subjects with Comorbidities. A Population-Based Study in Spain. Environmental Research, 215, Article ID: 114252. [Google Scholar] [CrossRef] [PubMed]
[31] Kwok, W.C., Leung, S.H.I., Tam, T.C.C., et al. (2023) Efficacy of MRNA and Inactivated Whole Virus Vaccines against COVID-19 in Patients with Chronic Respiratory Diseases. International Journal of Chronic Obstructive Pulmonary Disease, 18, 47-56. [Google Scholar] [CrossRef] 
[32] Fekete, M., Horvath, A., Santa, B., et al. (2023) COVID-19 Vaccination Coverage in Patients with Chronic Obstructive Pulmonary Disease—A Cross-Sectional Study in Hungary. Vaccine, 41, 193-200. [Google Scholar] [CrossRef] [PubMed]
[33] Durdevic, M., Arora, A., Durdevic, D., et al. (2021) Acute Copd Exacerbation after the Second Dose of Covid-19 Vaccine. Chest, 160, A1760. [Google Scholar] [CrossRef] 
[34] Mumm, T. and Elbashir, M. (2021) A Copd Exacerbation That Occurred after the MRNA Covid-19 Vaccine. Chest, 160, A1764. [Google Scholar] [CrossRef] 
[35] Qin, S.X., Cheng, F.W.T., Kwok, W.C., et al. (2024) Effectiveness and Respiratory Adverse Events Following Inactivated and MRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study. Drug Safety, 47, 135-146. [Google Scholar] [CrossRef] [PubMed]
[36] Davis, H.E., McCorkell, L., Vogel, J.M., et al. (2023) Long COVID: Major Findings, Mechanisms and Recommendations. Nature Reviews Microbiology, 21, 133-146. [Google Scholar] [CrossRef] [PubMed]
[37] Pérez-González, A., Araújo-Ameijeiras, A., Fernández-Villar, A., et al. (2022) Long COVID in Hospitalized and Non-Hospitalized Patients in a Large Cohort in Northwest Spain, a Prospective Cohort Study. Scientific Reports, 12, Article No. 3369. [Google Scholar] [CrossRef] [PubMed]
[38] Ceban, F., Kulzhabayeva, D., Rodrigues, N.B., et al. (2023) COVID-19 Vaccination for the Prevention and Treatment of Long COVID: A Systematic Review and Meta-Analysis. Brain, Behavior, and Immunity, 111, 211-229.
[39] Watanabe, A., Iwagami, M., Yasuhara, J., et al. (2023) Protective Effect of COVID-19 Vaccination against Long COVID Syndrome: A Systematic Review and Meta-Analysis. Vaccine, 41, 1783-1790. [Google Scholar] [CrossRef] [PubMed]
[40] 严祖喜, 杜小勇, 富冯峰, 等. 联合疫苗接种对慢性阻塞性肺疾病急性发作的影响[J]. 中国基层医药, 2018, 25(16): 2133-2135. [Google Scholar] [CrossRef] 
[41] Ofori-Anyinam, O., Leroux-Roels, G., Drame, M., et al. (2017) Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Co-Administered with a 23-Valent Pneumococcal Polysaccharide Vaccine versus Separate Administration, in Adults ≥ 50 Years of Age: Results from a Phase III, Randomized, Non-Inferiority Trial. Vaccine, 35, 6321-6328. [Google Scholar] [CrossRef] [PubMed]
[42] Nakashima, K., Aoshima, M., Ohfuji, S., et al. (2018) Immunogenicity of Simultaneous versus Sequential Administration of a 23-Valent Pneumococcal Polysaccharide Vaccine and a Quadrivalent Influenza Vaccine in Older Individuals: A Randomized, Open-Label, Non-Inferiority Trial. Human Vaccines & Immunotherapeutics, 14, 1923-1930. [Google Scholar] [CrossRef] [PubMed]
[43] 朱中奎, 卢希, 唐万琴, 等. 四价流感病毒裂解疫苗和23价肺炎球菌多糖疫苗在≥60岁老年人中同时接种的安全性评价[J]. 中华预防医学杂志, 2023, 57(9): 1412-1417. [Google Scholar] [CrossRef] [PubMed]
[44] Lazarus, R., Baos, S., Cappel-Porter, H., et al. (2021) Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines (ChAdOx1 Or BNT162b2) with Seasonal Influenza Vaccines in Adults in the UK (ComFluCOV): A Multicentre, Randomised, Controlled, Phase 4 Trial. The Lancet, 398, 2277-2287. [Google Scholar] [CrossRef] 
[45] Wang, S.Y., Duan, X.Q., Chen, B., et al. (2022) Immunogenicity and Safety of A SARS-CoV-2 Inactivated Vaccine (CoronaVac) Co-Administered with an Inactivated Quadrivalent Influenza Vaccine: A Randomized, Open-Label, Controlled Study in Healthy Adults Aged 18 to 59 Years in China. Vaccine, 40, 5356-5365. [Google Scholar] [CrossRef] [PubMed]
[46] Chen, H., Huang, Z., Chang, S., et al. (2022) Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered with Quadrivalent Split-Virion Inactivated Influenza Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine in China: A Multicentre, Non-Inferiority, Open-Label, Randomised, Controlled, Phase 4 Trial. Vaccine, 40, 5322-5332. [Google Scholar] [CrossRef] [PubMed]
[47] Jiang, B., Huang, Q., Jia, M., et al. (2022) Association between Influenza Vaccination and SARS-CoV-2 Infection and Its Outcomes: Systematic Review and Meta-Analysis. nese Medical Journal, 135, 2282-2293. [Google Scholar] [CrossRef] 
[48] Lewnard, JA., Bruxvoort, KJ., Fischer, H., et al. (2021) Prevention of Coronavirus Disease 2019 among Older Adults Receiving Pneumococcal Conjugate Vaccine Suggests Interactions between Streptococcus Pneumoniae and Severe Acute Respiratory Syndrome Coronavirus 2 in the Respiratory Tract. The Journal of Infectious Diseases, 225, 1710-1720. [Google Scholar] [CrossRef] [PubMed]
[49] 中华预防医学会, 中华预防医学会疫苗与免疫分会. 中国百日咳行动计划专家共识[J]. 中华流行病学杂志, 2021, 42(6): 955-965. [Google Scholar] [CrossRef] [PubMed]
[50] Global Initiative for Chronic Obstructive Lung Disease (2023) Global Strategy for the Prevention，Diagnosis and Management of COPD: 2023 REPORT.
https://goldcopd.org/2023-gold-report-2/
[51] Muñoz-Quiles, C., López-Lacort, M. and Díez-Domingo, J. (2018) Risk and Impact of Herpes Zoster among COPD Patients: A Population-Based Study, 2009-2014. BMC Infectious Diseases, 18, Article No. 203. [Google Scholar] [CrossRef] [PubMed]
[52] 中国医疗保健国际交流促进会皮肤科分会, 中华医学会皮肤性病学分会老年性皮肤病研究中心. 带状疱疹疫苗预防接种专家共识[J]. 中华医学杂志, 2022, 102(8): 538-543. [Google Scholar] [CrossRef] 
[53] 胡海峰, 詹家燚, 杜虹, 等. 肾综合征出血热患者2 245例的临床流行病学特征及预后危险因素分析[J]. 中华传染病杂志, 2023, 41(1): 70-76. [Google Scholar] [CrossRef] 

为你推荐